Seizure Reduction with Cenobamate in a Pediatric Patient with Refractory Generalized Epilepsy: A Case Report

Cenobamate (CNB) is a newer anti-seizure medication (ASM) approved by Food and Drug Administration (FDA) for adjunctive treatment of focal onset seizures in adults. Preclinical data indicates that CNB may have broad spectrum anti-seizure properties. A recently published small case study has reported that CNB led to improvement in seizure frequency in patients with generalized epilepsy. We present a pediatric patient with refractory generalized epilepsy who presented to our institution in status epilepticus consisting of bilateral facial and upper extremity twitching. After a prolonged hospitalization for refractory status epilepticus, he experienced a clinically significant reduction in seizure frequency with utilization of CNB. Our case adds to sparse literature available for the efficacy of utilizing CNB in a patient with refractory generalized epilepsy.